Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet throm- bosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015 24. 32. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement: inci- dence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 2017;10:686 97. 33. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:1566 76. 34. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139 51. 35. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093 104. 36. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non- valvular atrial fibrillation. N Engl J Med. 2011;365:883 91. 37. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981 92. 38. Edmunds LH Jr. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg. 1987;44:430 45. 39. Capodanno D, Angiolillo DJ. Antiplatelet therapy after implantation of bioresorbable vascular scaffolds: a review of the published data, practi- cal recommendations, and future directions. JACC Cardiovasc Interv. 2017;10:425 37. 40. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagu- lation in patients with atrial fibrillation. N Engl J Med. 2015;373:823 33. 11.3. Bridging Therapy 1. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative manage- ment of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141:e326S 50S. 2. Kearon C, Hirsh J. Management of anticoagulation before and after elec- tive surgery. N Engl J Med. 1997;336:1506 11. 3. 